Clinical trials: Thrombotic and Bleeding Events, open to volunteers
Antiphospholipid Syndrome (APS), Cohort Study
DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study
Antiphospholipid syndrome (APS) is a thrombotic disease requiring prolonged anticoagulation. Direct oral anticoagulants (DOACs) are indicated as 1st-line therapy in venous thrombosis, compared with VKAs, due to their easier…
- Conditions
- Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events
- Trial name
- DOWAPS (NCT06884384)
- Testing
- Additional blood collection during routine blood sampling at the inclusion (33.9 ml) and at the thrombotic recurrence (between 3.5 and 5 ml), Completion of a questionnaire on compliance with anticoagulant treatment, Completion of a questionnaire on satisfaction with treatment anticoagulant
- Where
- 13 sites in France
- Volunteers
- 310 people
- Sponsor
- Central Hospital, Nancy, France
Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO)
Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation
The aim of this observational pilot study is to evaluate the effectiveness and safety of low-molecular-weight heparin (LMWH) compared to unfractionated heparin (UFH) as anticoagulation in perioperative ECMO during bilateral lung…
- Conditions
- Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders
- Trial name
- LUX-ET-LT (NCT06868823)
- Where
- Czechia
- Volunteers
- 40 people
- Sponsor
- University Hospital, Motol
Antiphospholipid Syndrome (APS), Direct Oral Anticoagulants (DOACs)
OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs
This registry will make it possible to collect large-scale data on SAPL patients, particularly those treated with DOACs, in order to better assess the frequency of thrombotic and hemorrhagic events in this population of…
- Conditions
- Antiphospholipid Syndrome (APS), Direct Oral Anticoagulants (DOACs), Thrombotic and Bleeding Events, Safety
- Trial name
- OBSTINATE 2 (NCT06929182)
- Testing
- "non-high risk" thrombotic APS patients treated with DOAC
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Central Hospital, Nancy, France
Cirrhosis, Liver, Portal Hypertension
Cirrhotic and Non-cirrhotic Patients With Clinically Significant Portal Hypertension
Alterations in conventional coagulation tests in patients with cirrhosis and/or portal hypertension do not reliably predict bleeding risk, as hemostatic balance is complex and often compensated.
- Conditions
- Cirrhosis, Liver, Portal Hypertension, Clinically Significant Portal Hypertension(CSPH), Gastroesophageal Varices
- Trial name
- PREDIBLEED (NCT07405749)
- Where
- Italy
- Volunteers
- 2,500 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS